Otolith Labs

Executive Summary

Otolith Labs is a privately held medical device company developing a non-invasive, wearable therapeutic device for chronic vertigo using patented non-invasive Vestibular Resonance Therapy (nVRT). Founded in 2018 and headquartered in Washington, D.C., the company is pursuing FDA approval via the De Novo pathway for its first-of-its-kind device, which delivers precision signals to the vestibular system to reduce symptoms. Otolith Labs operates at the intersection of medical devices and neuroscience, targeting a large unmet need in vestibular disorders. While the company has not disclosed funding or valuation, its innovative approach and regulatory progress position it as a potential disruptor in the vertigo treatment market. Key risks include regulatory hurdles, clinical validation, and competition from existing therapies and emerging technologies.

Upcoming Catalysts (preview)

• Q4 2025FDA De Novo Classification Submission65% success
• Q2 2026Pivotal Clinical Trial Results60% success
• Q1 2026Series A or B Funding Round70% success